EMA begins review of Moderna’s vaccine for BA.4

Marco Cavalieri, head of vaccine strategy at the EMA, during the press conference.

The European Medicines Agency (EMA, in its acronym in English) has announced this Tuesday that at the end of September the moderna vaccine review (Spikevax) adapted to subvariants of Omicron BA.4 and BA.5. The announcement joins the approval, last week, of the Pfizer (Comirnaty) vaccine adapted to these same subvariants.

Marco Cavalieri, head of vaccine strategy at the EMA, has assured that the approval of this adapted vaccine “is based on total evidence”, as well as that thanks to these data they will be able to approve inoculations more quickly, for example, “Pfizer’s vaccine for the BA.1 subvariant has practically the same composition as the vaccine adapted to BA.4 and BA.5.”


Booster shots for children

On September 1, the EMA approved the vaccines adapted to the first Ómicron sublineagewhose detected side effects “were comparable to those of the originals, usually mild and short-lived”. In addition, it has been shown that “offer immunity against Omicron and the original strain of SARS-CoV-2 in previously vaccinated people.

On the other hand, Cavalleri has announced that the Pfizer vaccine has been approved for reinforcement of children between five and 11 years of age, as well as that the first data of the “primary” version of both inoculations for vaccinate children from six months to five years they are positive. “This study will be complete by the end of October,” she said.

Although it may contain statements, data or notes from health institutions or professionals, the information contained in Medical Writing is edited and prepared by journalists. We recommend the reader that any questions related to health be consulted with a health professional.

Leave a Comment

Your email address will not be published.